Astrazeneca PLC Profile



Odds of Distress

Analyze Filter    Fiscal Quarter End: December 31, 2019
Equity ratings for Astrazeneca PLC are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting September 9, 2019 and ending today December 8, 2019. Click here to learn more.

Astrazeneca PLC Profile

Next fiscal quarter end is expected on December 31, 2019. AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca PLC operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 64400 people. more
Astrazeneca PLC Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Astrazeneca PLC SEC Filings
Astrazeneca PLC SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameAstrazeneca PLC
ChairmanLeif JohanssonView All
Thematic Classifications
Active Investing Ideas
showing 2 out of 3 themes  View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Bond Rating
Healthcare, Drug Manufacturers - General
InstrumentUSA Stock View All
LocationUnited Kingdom
Business Address1 Francis Crick Avenue
Foreign Associates
ExchangeBATS Exchange
CIK Number0000901832
IndustryDrug Manufacturers?General
Phone44 20 3749 5000
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterSeptember 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestNovember 15, 2019
Astrazeneca PLC (AZN) is traded on BATS Exchange in USA. It is located in 1 Francis Crick Avenue and employs 64,400 people. Astrazeneca PLC is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with total capitalization of 124.48 B. Astrazeneca PLC runs under Healthcare sector within Drug Manufacturers?General industry. The entity has 2.62 B outstanding shares of which 9.65 M shares are presently shorted by investors with about 2.53 days to cover shorted positions. ASTRAZENECA PLC A has about 4.78 B in cash with 5.83 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82.
Check Astrazeneca PLC Probability Of Bankruptcy

Ownership Allocation (%)

Astrazeneca PLC Target Price Odds Analysis

Odds Below 47.68HorizonTargetOdds Above 47.68
81.81%30 days 47.68 18.02%
Based on normal probability distribution, the odds of Astrazeneca PLC to move above current price in 30 days from now is about 18.02 (This Astrazeneca PLC probability density function shows the probability of Astrazeneca PLC Stock to fall within a particular range of prices over 30 days) .

Astrazeneca PLC Top Holders

Astrazeneca PLC Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Wellington Management Group LlpCommon Shares66.9 MB
Primecap Management CoCommon Shares58.8 M2.6 B
View Astrazeneca PLC Diagnostics

Astrazeneca PLC Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Astrazeneca PLC Key Fundamentals

Astrazeneca PLC Against Markets

Did you try this?

Run Performance Analysis Now


Performance Analysis

Check effects of mean-variance optimization against your current asset allocation
All  Next Launch Module

Astrazeneca PLC Upcoming and Recent Events

Astrazeneca PLC Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportFebruary 13, 2020
Next Earnings ReportApril 24, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndFebruary 13, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

Astrazeneca PLC Corporate Filings

Astrazeneca PLC SEC Reporting

Unclassified Corporate Event

Astrazeneca PLC Corporate Directors

Marc Dunoyer Chief Financial Officer, Executive Director
Sherilyn McCoy Non-Executive Independent Director
Genevieve Berger Non-Executive Independent Director
Check also Trending Equities. Please also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.